Lantheus Holdings (FRA:0L8) 3-Year Revenue Growth Rate : 43.30% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings 3-Year Revenue Growth Rate?

Lantheus Holdings's Revenue per Share for the three months ended in Mar. 2024 was €4.86.

During the past 12 months, Lantheus Holdings's average Revenue per Share Growth Rate was 32.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 43.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 15.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was -2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Lantheus Holdings was 43.30% per year. The lowest was -20.10% per year. And the median was -9.35% per year.

Competitive Comparison of Lantheus Holdings's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantheus Holdings's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's 3-Year Revenue Growth Rate falls into.

Lantheus Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Lantheus Holdings (FRA:0L8) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Lantheus Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantheus Holdings (FRA:0L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

LNTH:USA 0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines